FREDERICK, Md., April 25, 2012 /PRNewswire/ -- BioElectronics Corporation (OTC-PINK: BIEL), the maker of disposable, inexpensive drug-free topical pain and healing devices, today announced the results of a customer survey. The results indicate that patients using BIEL's ActiPatch® therapy report a five-fold greater pain reduction than those using non-steroidal anti-inflammatory products such as ibuprofen and aspirin.
ActiPatch Therapy, which uses pulsed shortwave therapy based on large expensive machines used in clinics and hospitals, was most frequently used to treat lower back pain by participants in the survey. Lower back pain is a major health problem in western industrialized countries and a major cause of medical expenses and disablement.
"The most widely used OTC drugs have a significant number of side effects, are minimally effective and have only short-term symptomatic relief," said Ian Rawe, Ph.D., BioElectronics Director of Clinical Research. "In comparison, ActiPatch users who participated in the survey had a five-fold greater pain reduction than persons using non-steroidal anti-inflammatory drugs, based on a comparison to published clinical data. Additionally, with ActiPatch's all-day safe pain relief, people can resume their normal daily activities."
"We are very pleased by the results of our consumer survey, which confirms our clinical studies in which ActiPatch users as compared to users of OTC pain medications, have greater pain relief and an improved quality of life," Dr. Rawe said. "An increased consumer awareness of the dangers of overuse of oral analgesics such as acetaminophen and non-steroidal anti-inflammatory drugs has significantly altered the competitive landscape for pain management therapeutics. There is significant need for an improved efficacy, competitively priced over-the-counter therapeutic agent with no side-effects."
Results of the survey, which also show that patients would re
|SOURCE BioElectronics Corporation|
Copyright©2010 PR Newswire.
All rights reserved